

# ASTELLAS PHARMA INC.

ISIN: JP3942400007 WKN: 4503 Asset Class: Stock

## Company

2024/06/26 08:00:00



**Price**  
**1,584.00**  
JPY

**Difference** ▲ 0.35%(5.50)



## Contact Details

ASTELLAS PHARMA INC. Tel: +81-3-3244-3000  
 -- Fax: +  
 2-5-1 Nihonbashi-Honcho, Chuo-Ku Web: <http://www.astellas.com>  
 103-8411 Tokyo E-mail: -

## Company Profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

## Financial figures, Fiscal year: from 01.04. to 31.03.

Financial figures	2024		2023		2022	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	1,194,730,000,000		1,049,954,000,000		923,354,000,000	
<b>Common stock capital</b>		103,001,000,000		103,001,000,000		103,001,000,000
<b>Fixed assets</b>	2,374,873,000,000		1,406,564,000,000		1,409,041,000,000	
<b>Equity capital of a company</b>		1,595,988,000,000		1,507,954,000,000		1,460,308,000,000
<b>Cash and cash equivalents</b>	335,687,000,000		376,840,000,000		315,986,000,000	
<b>Accrued liabilities</b>		76,642,000,000		67,859,000,000		77,207,000,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		1,285,725,000,000		726,034,000,000		687,411,000,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		687,891,000,000		222,530,000,000		184,675,000,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		41,409,000,000		37,162,000,000		46,631,000,000
<b>Total assets</b>	3,569,603,000,000	3,569,603,000,000	2,456,518,000,000	2,456,518,000,000	2,332,395,000,000	2,332,395,000,000

## Balance notes

	2024	2023	2022
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	14,754	14,484	14,522
<b>Equity ratio</b>	44.71%	61.39%	62.61%
<b>Debt-equity ratio</b>	123.66%	62.90%	59.72%

## Others

	2024	2023	2022
<b>Tax Expense Rate</b>	28.17%	25.66%	20.97%

# ASTELLAS PHARMA INC.

ISIN: JP3942400007 WKN: 4503 Asset Class: Stock

## Income statement

	2024	2023	2022
<b>Turnover</b>	1,603,672,000,000	1,518,619,000,000	1,296,163,000,000
<b>Net income</b>	17,045,000,000	98,714,000,000	124,086,000,000
<b>EBIT</b>	169,507,000	764,120,800	947,256,800
<b>Operating income before taxes</b>	28,134,000,000	131,101,000,000	156,397,000,000
<b>Cash Flow</b>	181,325,000,000	332,325,000,000	258,160,000,000
<b>Net interest income</b>	-596,000,000	1,589,000,000	-4,155,000,000
<b>Research and development expenses</b>	294,187,000,000	276,128,000,000	246,010,000,000
<b>Income taxes</b>	7,924,000,000	33,647,000,000	32,800,000,000
<b>Result from investments in subsidiaries, associates and other</b>	-3,165,000,000	1,260,000,000	489,000,000
<b>Revenues per employee</b>	641,295	618,603	526,605

## Board of Directors

Kenji Yasukawa	Chairman of Supervisory Board
Eriko Sakurai	Member of Supervisory Board
Haruko Shibumura	Member of Supervisory Board
Hiroko Sakai	Member of Supervisory Board
Hiroo Sasaki	Member of Supervisory Board
Hiroshi Kawabe	Member of Supervisory Board
Katsuyoshi Sugita	Member of Supervisory Board
Mamoru Sekiyama	Member of Supervisory Board
Mika Nakayama	Member of Supervisory Board
Noriyuki Uematsu	Member of Supervisory Board
Takashi Tanaka	Member of Supervisory Board
Tatsuro Ishizuka	Member of Supervisory Board
Tomokazu Fujisawa	Member of Supervisory Board

## Members of Management Board

Kenji Yasukawa	Chairman of Managing Board
Bernie Zeiher	Member of Executive Committee
Catherine Levitt	Member of Executive Committee
Fumiaki Sakurai	Member of Executive Committee
Hideki Shima	Member of Executive Committee
Minoru Kikuoka	Member of Executive Committee
Naoki Okamura	Member of Executive Committee
Yoshihitsu Shitaka	Member of Executive Committee
Yukio Matsui	Member of Executive Committee